AMR Action Fund Expands Portfolio with Two New Investments

April 27, 2023, Boston, MA: The AMR Action Fund announced this week that it has invested in Vedanta Biosciences and Pattern Bioscience.

Vedanta Biosciences is a clinical-stage company whose lead candidate, VE303, is in development for the prevention of recurrent Clostridioides difficile infection, which the U.S. Centers for Disease Control and Prevention has classified as an “urgent threat.”

It is estimated that approximately 500,000 C. difficile infections occur each year in the U.S., causing tens of thousands of deaths. To take on this growing health threat, Vedanta is developing a potential new category of oral therapies based on defined bacterial consortia. The company said that one of the primary uses of the funding will be to launch a pivotal Phase 3 trial in recurrent C. difficile infections.

Pattern Bioscience is developing a diagnostics platform to rapidly identify bacterial pathogens and determine their antibiotic susceptibility. The company’s novel technology is based on single-cell analysis of microorganisms combined with machine learning tools.

The lack of rapid diagnostics and susceptibility testing is a significant challenge globally that imperils patients and undermines antibiotic stewardship efforts. Current standard-of-care cultures can take up to four days to provide a definitive diagnosis for critically ill patients. Pattern’s aim is to develop a platform that can deliver accurate results in a matter of hours.

To learn more about our investment in Vedanta, please click here.

To learn more about our investment into Pattern, please click here.

For more information contact Chris Sweeney: chris.sweeney@amractionfund.com.